新增的 3 家生物技术与生命科学企业实体具体名单如下： 14. Beijing Tianyi Huiyuan Biotech（北京天一辉远生物科技有限公司） 15. Beijing Tsingke Biotech Co., Ltd. （北京擎科生物科技股份有限公司） /生物制造产业社群/ 让上下游聚在一起, 未来食农、绿色化工、大健康、美妆个护 等产业同行❤️↓ 16. Sangon Biotech (Shanghai) Co., Ltd. （生工生物工程（上海）股份有限公司） 截至目前，美国已经将多家生物技术与合成生物企业列入"黑名单"，更多阅读如下： 继关税之后，美国对华"生物科技战"再次拉响！ 美国《生物安全法》风波扩散，又一家合成生物公司被关注！ 全球政策进展 | 美国 商务部工业与安全局 【SynBioCon】 获 悉，9 月 12 日，美国商务部工业与安全局（ BIS ）发布公告，以存在"违背美国国家安全或外交政策利益"的行为为由，宣布将 23 家 中国实体列入实体清单。其 中 3 家来自生物技术与生命科学领域 。 被列入实体清单的实体，所有受 EAR 管辖的物项对其出口均须申请许可证；许可证审查 ...

Financial Data and Key Metrics Changes - The company generated revenue of $665 million in Q1 2025, resulting in 4% organic growth, with a 1% headwind from foreign exchange [27][31] - Adjusted EPS for the quarter was $1.01, exceeding expectations of $0.93 to $0.95 [7][29] - Adjusted operating margins were reported at 25.6%, slightly up year-over-year and above expectations [28] Business Line Data and Key Metrics Changes - Life Sciences segment revenue was $340 million, up 1% reported and 2% organically, with low single-digit growth in pharma biotech customers and a decline in academic and government customers [32] - Diagnostics segment revenue reached $324 million, up 3% reported and 5% organically, driven by high single-digit growth in immunodiagnostics [33] Market Data and Key Metrics Changes - The Americas and Europe experienced mid-single-digit growth, while Asia saw low single-digit growth, with China also growing in low single digits [31] - U.S. academic customers, representing over 5% of total revenue, showed cautious spending due to uncertainties in funding [23][24] Company Strategy and Development Direction - The company is focused on maintaining strong organic growth and operational agility to navigate macroeconomic challenges [5][20] - A recent expanded alliance with Genomics England aims to enhance newborn genomic sequencing capabilities, positioning the company as a leader in this area [9] - The software business, representing about 8% of total revenue, grew over 20% organically in Q1 and is expected to continue strong growth [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's resilience and ability to adapt to changing market conditions, reaffirming a full-year adjusted EPS outlook of $4.9 to $5 [19][37] - The company anticipates a gross impact of approximately $135 million from tariffs, but expects to mitigate most of this through proactive measures [18][19] Other Important Information - The company repurchased $154 million of its shares in Q1, reducing the outstanding share count to 119.4 million [7][29] - The net debt to adjusted EBITDA leverage ratio was reported at 2.4 times, with all debt being fixed rate [30] Q&A Session Summary Question: Can you talk about the tariff impact and what products are affected? - Management indicated that they have been proactive in adjusting their supply chain to mitigate the $135 million gross tariff impact, focusing on products sold from the U.S. to China [41][43] Question: What are the expectations for the Life Sciences segment? - The Life Sciences segment is expected to see low single-digit growth, with instrumentation under pressure but solid growth in reagents [45][48] Question: How is the company managing its exposure in China? - The company expects low single-digit growth in China, with a slight decline in Life Sciences and mid-single-digit growth in Diagnostics [56] Question: What is the outlook for the software business? - The software business is expected to continue strong double-digit growth, with a focus on expanding into new markets [62][90] Question: What are the long-term margin expectations? - Long-term operating margin expectations remain unchanged, with a focus on SG&A volume leverage as growth continues [104]